LISCure Biosciences Inc.

LISCure Biosciences Provides Novel Therapeutics to Patients with Refractory Diseases Using the LMT Platform. LISCure is developing the world’s first injectable immuno-oncology program using non-pathogenic microorganisms. We focus on the development of first-in-class new drugs against diseases for which existing microbiome treatments have been rarely attempted. We are developing therapeutics for diseases with high unmet medical needs, such as immuno-oncology, metabolic diseases, autoimmune diseases, and neurodegenerative diseases, using a single strain and microbial-derived metabolites, extracellular vesicles (EVs) such as exosomes. To continue providing new treatments for patients, we developed the LMT (LISCure Microbiology-based Technology) platform to discover and identify microorganisms that are scientifically proven safe and effective for various therapeutic areas.